We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

189 hedge funds and large institutions have $459M invested in Catalyst Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 61 increasing their positions, 72 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

407% more call options, than puts

Call options by funds: $715K | Put options by funds: $141K

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

4.5% more ownership

Funds ownership: 68.95% → 73.45% (+4.5%)

1% more funds holding

Funds holding: 187 → 189 (+2)

15% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 72

21% less capital invested

Capital invested by funds: $583M → $459M (-$125M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
189
Holders Change
+2
Holders Change %
+1.07%
% of All Funds
3.18%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
24
Increased
61
Reduced
72
Closed
18
Calls
$715K
Puts
$141K
Net Calls
+$574K
Net Calls Change
+$478K

Top Buyers

1
AC
Armistice Capital
New York
+$13.4M
2
Millennium Management
Millennium Management
New York
+$11.4M
3
State Street
State Street
Massachusetts
+$6.01M
4
Goldman Sachs
Goldman Sachs
New York
+$5.92M
5
N
Nuveen
North Carolina
+$5.51M

Top Sellers

1
Federated Hermes
Federated Hermes
Pennsylvania
-$4.81M
2
Two Sigma Investments
Two Sigma Investments
New York
-$4.49M
3
BlackRock
BlackRock
New York
-$3.6M
4
Wells Fargo
Wells Fargo
California
-$2.5M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$4.43M +$2.1M +286,556 +83%
AllianceBernstein
27
AllianceBernstein
Tennessee
$3.63M +$2.81M +383,311 +285%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.51M -$504K -68,776 -12%
AQR Capital Management
29
AQR Capital Management
Connecticut
$3.42M +$543K +73,989 +18%
Two Sigma Investments
30
Two Sigma Investments
New York
$3.25M -$4.49M -611,957 -57%
Russell Investments Group
31
Russell Investments Group
United Kingdom
$3.07M +$257K +35,066 +9%
GCM
32
Gables Capital Management
Florida
$3.06M -$22K -3,000 -0.7%
Los Angeles Capital Management
33
Los Angeles Capital Management
California
$2.58M +$962K +131,159 +55%
Victory Capital Management
34
Victory Capital Management
Texas
$2.56M -$109K -14,884 -4%
CSS
35
Cubist Systematic Strategies
Connecticut
$2.48M +$403K +54,924 +18%
SEI Investments
36
SEI Investments
Pennsylvania
$2.44M +$392K +53,452 +18%
EI
37
EAM Investors
California
$2.38M -$187K -25,473 -7%
UBS Group
38
UBS Group
Switzerland
$2.28M +$77K +10,497 +3%
State Board of Administration of Florida Retirement System
39
State Board of Administration of Florida Retirement System
Florida
$2.21M +$144K +19,607 +7%
FA
40
Friess Associates
Delaware
$2.14M -$1.96M -266,792 -47%
Man Group
41
Man Group
United Kingdom
$2.14M -$1.88M -256,100 Closed
GC
42
Globeflex Capital
California
$2.13M – – –
Fisher Asset Management
43
Fisher Asset Management
Washington
$2.04M +$223K +30,429 +12%
PC
44
Prairiewood Capital
North Dakota
$1.81M -$3.31K -452 -0.2%
AAM
45
Advisors Asset Management
Colorado
$1.74M +$834K +113,743 +84%
EGI
46
EAM Global Investors
California
$1.72M -$343K -46,789 -16%
AIMCA
47
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.68M -$207K -28,217 -11%
RJFSA
48
Raymond James Financial Services Advisors
Florida
$1.66M -$7.79K -1,062 -0.4%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.62M – – –
BGIM
50
Brandywine Global Investment Management
Pennsylvania
$1.56M -$238K -32,400 -13%
1
2
3 4 5

CPRX Hedge Fund Activity: Q2 2022 in Review

189 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2022, worth a combined $459M — down 21% from $583M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CPRX positions and 18 closed out — a net gain of 6 holders — while 61 added to existing stakes and 72 trimmed.

The largest buyer was Armistice Capital, adding an estimated $13.4M. The largest seller was Federated Hermes, cutting an estimated $4.81M.

  • 189 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2022, up from 187 in Q1 2022.
  • Funds reported $459M of Catalyst Pharmaceutical stock for Q2 2022, down 21% quarter-over-quarter.
  • 24 funds opened new Catalyst Pharmaceutical positions in Q2 2022 and 18 closed out, a net change of +6 holders.
  • The largest Catalyst Pharmaceutical buyer in Q2 2022 was Armistice Capital, an estimated $13.4M added.
  • The largest Catalyst Pharmaceutical seller in Q2 2022 was Federated Hermes, an estimated $4.81M sold.

Based on aggregated 13F filings for Q2 2022.